Results 251 to 260 of about 326,995 (379)

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

Angewandte Chemie, EarlyView.
Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker, Adrian Pui Ting Ho, Laura S. Itzhaki, Ljiljana Fruk   +3 more
wiley   +2 more sources

The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. [PDF]

Cells, 2021
Beumer-Chuwonpad A, Taggenbrock RLRE, Ngo TA, van Gisbergen KPJM.   +3 more
europepmc   +1 more source

Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy

, 2001
Daniela Montagna, Rita Maccario, Franco Locatelli, Vittorio Rosti, Young Yang, Peggy Farness, Antonia Moretta, Patrizia Comoli, Enrica Montini, Antonella Vitiello   +9 more
openalex   +1 more source

Enhancing siRNA effects in T cells for adoptive immunotherapy [PDF]

, 2005
Kevin V. Morris, Daniela Castanotto, Zaid Al‐Kadhimi, Michael C. Jensen, John J. Rossi, Laurence J.N. Cooper   +5 more
openalex   +1 more source

Research advancements and evaluation of multifactor‐induced murine models for gastric cancer

Animal Models and Experimental Medicine, EarlyView.
Murine models for gastric cancer. Abstract As one of the most prevalent gastrointestinal malignancies in humans, gastric cancer (GC) is often detected at an advanced stage, resulting in a poor prognosis and ranking it the fifth leading cause of cancer‐related deaths.
Yiqing Wang, Liang Zhang, Weixu Feng, Wanfeng Liu, Xiangyang Xue, Shiyu Feng   +5 more
wiley   +1 more source

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy. [PDF]

Inflamm Regen
Ito Y, Inoue S, Kagoya Y.
europepmc   +1 more source

Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study. [PDF]

Front Immunol, 2023
Mestiri S, Merhi M, Inchakalody VP, Taib N, Smatti MK, Ahmad F, Raza A, Ali FH, Hydrose S, Fernandes Q, Ansari AW, Sahir F, Al-Zaidan L, Jalis M, Ghoul M, Allahverdi N, Al Homsi MU, Uddin S, Jeremijenko AM, Nimir M, Abu-Raddad LJ, Abid FB, Zaqout A, Alfheid SR, Saqr HMH, Omrani AS, Hssain AA, Al Maslamani M, Yassine HM, Dermime S.   +29 more
europepmc   +1 more source

Use of ¹⁸F‐FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions [PDF]

, 2005
D. P. Hart, Irit Avivi, Kirsty Thomson, Karl S. Peggs, Emma Morris, Anthony H. Goldstone, David C. Linch, Peter J. Ell, Jamshed Bomanji, Stephen Mackinnon   +9 more
openalex   +1 more source

Advances on Albumin‐Based Carriers for Anticancer Drug Delivery

Advanced NanoBiomed Research, EarlyView.
This study systematically classifies the drug delivery modes of albumin by examining the characteristics of its surface‐active groups and internal binding sites. It provides an in‐depth analysis of various drug delivery strategies and their corresponding targeting mechanisms.
Ruoli Zhou, Rongbin Zhong, Zhonghui Luo, Hua Wei, Cui‐Yun Yu   +4 more
wiley   +1 more source

A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation. [PDF]

PLoS One
Ohira M, Imaoka Y, Sato K, Imaoka K, Bekki T, Yano T, Nakano R, Sakai H, Kuroda S, Tahara H, Ide K, Kobayashi T, Tanaka Y, Tanaka J, Ohdan H.   +14 more
europepmc   +1 more source